Dr Rini on Sustained Survival Outcomes After Completion of Pembrolizumab and Axitinib in ccRCC
June 7th 2023Brian I. Rini, MD, FASCO, discusses long-term survival outcomes in patients with advanced clear cell renal cell carcinoma who received frontline pembrolizumab and axitinib in the phase 3 KEYNOTE-426 trial.
Read More